Articles By Wayne Koberstein, Executive Editor

Companies To Watch: United Neuroscience
Companies To Watch: United Neuroscience “We are a vaccine company,” says CEO Mei Mei Hu. “We’re developing a new class of vaccines for endogenous proteins, leveraging a commercially successful technology platform in which we’ve invested more than 20 years.”  Continue Reading...
  • Our Annual Cancer Immuno-oncology Update 2018
    Our Annual Cancer Immuno-oncology Update 2018

    This year’s IO update is more compact because the essential story has contracted. The odds of success have shifted dramatically and disparately among the various players — all due to Merck’s Keytruda.

  • Companies To Watch: Acceleron
    Companies To Watch: Acceleron

    Acceleron has four drugs in development in the hematology, neuromuscular, and pulmonary disease areas. Its lead drug luspatercept has completed Phase 3 trials for treating myelodysplastic syndromes (MDS).

  • Fibrocell: Where Gene Therapy Meets Synthetic Biology
    Fibrocell: Where Gene Therapy Meets Synthetic Biology

    “We had to decide whether to spend a lot of money to bring on a sales force and marketing team, and expand manufacturing to meet demand, or take our resources and refocus them on these rare disorders.”  

  • Alexis Howerton On Starting Up From New Science
    Alexis Howerton On Starting Up From New Science

    Alexis Howerton is a first-time pharma CEO who saw potential in an older drug class that had failed in its targeted indications. She then jumped feet first into obtaining the ideal candidate compound and starting a company to develop it.

  • Aurinia: Teamwork Twice
    Aurinia: Teamwork Twice

    From founding the company to funding it, the CEO of Aurinia Pharmaceuticals explains the genesis of the company and why he left retirement to return to guide the company.

  • Chris Garabedian On How To Drive Drug Development
    Chris Garabedian On How To Drive Drug Development

    Drawing from his 27 years in the pharma industry, Chris Garabedian shares useful lessons for combining business savvy and scientific leadership in drug development.

  • Companies To Watch: Sensorion
    Companies To Watch: Sensorion

    This French company is addressing vertigo and hearing loss inside the inner ear.

  • Industry Explorers Blaze On: Vicki Sato — The Biology Biz
    Industry Explorers Blaze On: Vicki Sato — The Biology Biz

    Beginning her career with the query — how does biology cause disease? — Vicki Sato progressed to business, turning scientific understanding into new therapeutic drugs. Sato has been a biopharma leader since the industry’s formative years, helping drive the growth of Biogen and Vertex, and she is still guiding new companies today.

  • Companies To Watch: Landos Biopharma
    Companies To Watch: Landos Biopharma

    Our company to watch this month is Landos Biopharma, which is aiming for better targeting and better delivery of treatments for GI and other autoimmune diseases.

  • Industry Explorers Blaze On: Anna Protopapas
    Industry Explorers Blaze On: Anna Protopapas

    Her mother was the first woman of her village in Cyprus to go to high school. Anna Protopapas shared her mother’s drive to bypass all barriers, and she now runs the biopharma company Mersana, after many years in the leadership of Millennium and Takeda.

  • Reata Pharmaceuticals: Return & Reach Beyond
    Reata Pharmaceuticals: Return & Reach Beyond

    Reata refused to take what seemed like a dead-end trial as a losing proposition. Instead, the company went to work mining the trial for the very insights that subsequently saved it.

  • Companies To Watch: CytoDyn
    Companies To Watch: CytoDyn

    CytoDyn’s expressed ambitions seem bold but reasonably free of hyperbole. It is only natural to hope for the best possible outcome here, considering the obvious need for new HIV and other immunological therapies.

  • Companies To Watch: AmpliPhi Biosciences
    Companies To Watch: AmpliPhi Biosciences

    AmpliPhi Biosciences is pushing bacteriophage-therapy development for drug-resistant infections — not to replace, but possibly to augment antibiotics.

  • Companies To Watch Roundup 2017
    Companies To Watch Roundup 2017

    We check in with the companies we profiled from this section in 2017 to see what has changed … if anything.

More From Wayne Koberstein
Wayne Koberstein

Wayne Koberstein


Wayne Koberstein is a 30-year veteran of the publishing industry, with extensive experience in publishing, communications, and business development. Wayne has interviewed and profiled more than 300 top executives in pharmaceutical companies, as well as major regulatory and health care leaders, around the world. He has also created special media projects and conferences, in addition to serving widely as speaker, moderator, and advisor for industry meetings.